Core Viewpoint - A class action has been filed against Inovio Pharmaceuticals, Inc. for allegedly misleading investors regarding the approval process of its CELLECTRA device and the INO-3107 Biologics License Application (BLA) [1][2]. Group 1: Allegations and Issues - The complaint alleges that Inovio failed to disclose deficiencies in the manufacturing of its CELLECTRA device, which impacted the likelihood of submitting the INO-3107 BLA to the FDA by the previously projected timeline [2]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [2]. - On August 8, 2024, Inovio announced a delay in the submission of the INO-3107 BLA to mid-2025 due to manufacturing issues, resulting in a stock price drop of $0.27 per share, or 3.1%, closing at $8.44 on August 9, 2024 [3]. Group 2: Regulatory Developments - On December 29, 2025, Inovio announced that the FDA accepted the INO-3107 BLA for standard review rather than accelerated review, as the company did not provide adequate information for the latter [4]. - Following this announcement, Inovio's stock price fell by $0.56 per share, or 24.45%, closing at $1.73 on December 29, 2025 [4]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Inovio, with a deadline to submit papers to serve as lead plaintiff by April 7, 2026 [5].